EQUITY

Class I - USD

DREW FIGDOR Portfolio Manager, TIG Advisors LLC

We look for wide spreads and complex mergers where our research can add value.

GLOBAL MERGER ARBITRAGE FUND

The Lyxor/Tiedemann Arbitrage Strategy Fund invests in global securities that are, or may become, subject to a corporate action or event and will trade primarily in connection with announced transactions. Such an event might include a tender offer, merger, liquidation, recapitalization, spinoff, proxy contest, exchange offer, leveraged buyout or bankruptcy. The strategy seeks to maximize risk-adjusted returns by investing in complex deals with wide price spreads.

HIGH CONVICTION, NON-CORRELATED STRATEGY


The fund exhibits little to no correlation to broad asset classes: it takes both long and short positions and focuses on events of up to 30 days within the merger arbitrage process. Taking positions in announced and overlooked deals, the team can take larger position sizes on deals where the team has strong conviction. Only eight of the thousands of deals it has traded have approached the 2.5% limit at which it sells a position to stop losses.

EXPERIENCED TEAM, EXTENSIVE RESEARCH

Drew Figdor has been the portfolio manager since 1993, and oversees a collaborative investment process. The team leverages public information sources and a network of brokers to identify opportunities. They carefully evaluate a merger arbitrage trade's spread and their ability to trade around the event prior to investment.

| SUB-MANAGER / ADVISOR DETAILS* | | | | | | |
|----------------------------------|----------------|--|--|--|--|--|
| Strategy Event Driven & Risk Arl | | | | | | |
| Geographical zone Global | | | | | | |
| Date firm incorporation | January 1980 | | | | | |
| Strategy inception date | January 1993 | | | | | |
| AuMs - Firm | \$ 5.5 billion | | | | | |
| AuMs - Strategy | \$ 3.1 billion | | | | | |
| Total firm staff | 41 | | | | | |
| *Information as and of May 2022 | | | | | | |

CUMULATIVE SIMULATED STRATEGY AND REAL FUND PERFORMANCE



Performance has been presented net of fees. THE FIGURES RELATING TO SIMULATED PAST PERFORMANCE REFER OR RELATE TO PAST PERIODS AND ARE NOT A RELIABLE INDICATOR OF FUTURES RESULTS. THIS ALSO APPLIES TO HISTORICAL MARKET DATA. It should not be assumed that the performance of the Fund in the future will be comparable or is indicative of the performance information presented here. Performance shown from January 1993 to February 2013 is hypothetical and based on an indicative simulation . All simulated performances are based on a leverage amount of 1.5 : 1 on the TIG Arbitrage Associates L.P (the "Arb Base Fund"). However, the additional financing costs of this increased leverage have not been deducted from the figures presented above. Additionally, increased leverage amounts would require the borrowing of additional securities to initiate 'short' positions. There is no guarantee that such additional securities would be available. While this data includes actual underlying performance returns of the Arb Base Fund, no fund or account, including the Arb Base Fund, was actually traded using this imputed leverage amount. Performance shown from March 2013 represents that of the Fund.

| KEY FIGURES | | | | | | |
|---|--------|--|--|--|--|--|
| Fund Size - USD M | 1976.6 | | | | | |
| Annualized Rate of Return* | 9.4% | | | | | |
| Annualized Volatility* | 4.9% | | | | | |
| Sharpe ratio* | 1.4 | | | | | |
| *Since Strategy Inception: January 1993 | | | | | | |



Information as of the end of the month indicated at the top of this page.

*Information as end of May 2022

THIS DOCUMENT IS FOR THE EXCLUSIVE USE OF INVESTORS ACTING ON THEIR OWN ACCOUNT AND CATEGORIZED EITHER AS "ELIGIBLE COUNTERPARTIES" OR "PROFESSIONAL CLIENTS" WITHIN THE MEANING OF MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE 2004/39/EC. NOT FOR U.S INVESTORS.



LYXOR / TIEDEMANN ARBITRAGE STRATEGY FUND

Class I - USD

SIMULATED STRATEGY AND FUND PERFORMANCE (%)

| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | J | F | М | Α | М | J | J | Α | S | 0 | Ν | D | YTD |
|--|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 2022 | -0.81 | 1.41 | -0.21 | -0.24 | -2.42 | -1.06 | | | | | | | -3.32 |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | 2021 | 2.50 | 0.16 | -0.66 | 2.01 | 0.30 | -0.22 | -1.07 | 1.20 | -0.34 | 0.41 | 0.52 | 0.03 | 4.89 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2020 | 0.23 | 0.08 | -5.35 | 4.16 | 0.11 | 0.31 | 0.62 | -0.49 | 0.94 | 0.78 | 1.38 | 1.77 | 4.36 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2019 | 0.59 | -0.04 | 0.56 | 0.47 | -0.59 | -0.86 | 0.43 | -0.38 | 0.53 | 0.63 | 0.85 | 0.65 | 2.85 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2018 | 1.32 | 1.20 | -1.71 | 0.65 | 1.00 | 1.89 | -0.96 | 0.03 | 0.78 | 0.15 | 1.32 | 1.12 | 6.92 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2017 | -0.42 | 1.24 | -0.71 | 2.64 | 0.94 | 0.23 | 0.63 | -0.11 | 0.38 | 0.35 | -1.60 | 0.99 | 4.58 |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | 2016 | -0.70 | 0.75 | 2.67 | -2.33 | 1.09 | 1.04 | 1.04 | 1.27 | 0.81 | -1.24 | 0.48 | 0.78 | 5.69 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2015 | 0.00 | 1.23 | 0.64 | 1.17 | 1.24 | -1.12 | -1.47 | -2.13 | -1.81 | 0.51 | -0.33 | 2.37 | 0.17 |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | 2014 | 1.23 | 1.05 | -1.21 | 0.68 | 0.53 | 1.74 | -0.99 | 0.04 | -0.72 | -5.14 | 1.36 | 0.40 | -1.21 |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | 2013 | -0.54 | 0.60 | 1.60 | 2.27 | 2.11 | -0.04 | 1.83 | -0.10 | 0.75 | 1.06 | 0.08 | 0.16 | 10.18 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2012 | 1.40 | 1.05 | 1.01 | 0.00 | -0.18 | -0.07 | 0.15 | 1.37 | 0.10 | -0.66 | 1.68 | 0.71 | 6.73 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2011 | 0.85 | 1.21 | 0.44 | 1.26 | -1.83 | -0.42 | -0.79 | -1.06 | 1.77 | 2.71 | 1.06 | -0.07 | 5.15 |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | 2010 | 0.54 | 0.90 | 0.44 | -0.24 | -1.55 | 0.88 | 3.48 | 0.64 | 4.06 | -1.83 | -1.21 | 0.45 | 6.58 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2009 | 1.21 | 1.81 | 4.44 | 1.71 | 1.58 | 1.95 | 0.09 | 0.49 | 1.14 | 0.38 | 0.98 | 1.21 | 18.30 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2008 | -2.06 | 0.94 | -1.83 | 3.98 | 1.82 | -4.07 | 0.83 | 3.01 | -5.04 | -2.02 | 0.35 | 5.85 | 1.18 |
| 2005 0.32 0.42 0.69 0.47 0.74 1.04 0.62 0.62 0.36 -2.62 1.57 0.88 5. 2004 0.82 0.60 0.16 -0.05 0.38 -0.22 -0.59 0.05 0.05 0.65 1.08 0.75 3. 2003 0.34 0.06 0.50 0.56 1.00 1.27 0.11 -0.11 0.00 0.16 0.22 0.22 4. 2002 0.56 0.00 0.17 0.22 0.06 0.00 -1.40 0.73 0.1 2001 0.58 0.92 -0.29 1.09 1.71 0.40 0.73 0.45 -1.29 0.11 -0.34 0.28 4. 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 < | 2007 | 2.54 | 0.40 | 1.54 | 3.13 | 3.88 | -0.65 | -0.13 | 1.27 | 2.55 | 2.41 | -2.63 | -1.01 | 13.91 |
| 2004 0.82 0.60 0.16 -0.05 0.38 -0.22 -0.59 0.05 0.05 0.65 1.08 0.75 33 2003 0.34 0.06 0.50 0.56 1.00 1.27 0.11 -0.11 0.00 0.16 0.22 0.22 4.4 2002 0.56 0.00 0.17 0.22 0.06 0.00 -1.40 0.73 0.1 2001 0.58 0.92 -0.29 1.09 1.71 0.40 0.73 0.45 -1.29 0.11 -0.34 0.28 4.4 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 | 2006 | 3.03 | 2.57 | 0.00 | 1.98 | 0.98 | 1.26 | 2.41 | 0.38 | 1.56 | 1.87 | 0.69 | 1.52 | 19.80 |
| 2003 0.34 0.06 0.50 0.56 1.00 1.27 0.11 -0.11 0.00 0.16 0.22 0.22 4. 2002 0.56 0.00 0.17 0.22 0.06 0.00 0.17 0.22 0.06 0.00 -1.40 0.73 0. 2001 0.58 0.92 -0.29 1.09 1.71 0.40 0.73 0.45 -1.29 0.11 -0.34 0.28 4. 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 | 2005 | 0.32 | 0.42 | 0.69 | 0.47 | 0.74 | 1.04 | 0.62 | 0.62 | 0.36 | -2.62 | 1.57 | 0.88 | 5.17 |
| 2002 0.56 0.00 0.17 0.22 0.06 0.00 0.17 0.22 0.06 0.00 -1.40 0.73 0. 2001 0.58 0.92 -0.29 1.09 1.71 0.40 0.73 0.45 -1.29 0.11 -0.34 0.28 4. 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 200 1996 1.03 0.96 | 2004 | 0.82 | 0.60 | 0.16 | -0.05 | 0.38 | -0.22 | -0.59 | 0.05 | 0.05 | 0.65 | 1.08 | 0.75 | 3.73 |
| 2001 0.58 0.92 -0.29 1.09 1.71 0.40 0.73 0.45 -1.29 0.11 -0.34 0.28 4. 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 200 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 15 1995 1.57 3.20 1 | 2003 | 0.34 | 0.06 | 0.50 | 0.56 | 1.00 | 1.27 | 0.11 | -0.11 | 0.00 | 0.16 | 0.22 | 0.22 | 4.41 |
| 2000 2.27 2.11 1.23 3.16 1.26 2.00 1.42 1.71 1.81 1.43 1.83 1.11 23 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 200 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 15 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.6 | 2002 | 0.56 | 0.00 | 0.17 | 0.22 | 0.06 | 0.00 | 0.17 | 0.22 | 0.06 | 0.00 | -1.40 | 0.73 | 0.78 |
| 1999 0.77 1.31 1.75 3.92 2.43 2.24 1.43 0.85 1.97 1.87 1.98 1.55 24 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 200 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 155 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 2001 | 0.58 | 0.92 | -0.29 | 1.09 | 1.71 | 0.40 | 0.73 | 0.45 | -1.29 | 0.11 | -0.34 | 0.28 | 4.40 |
| 1998 0.34 2.23 1.44 1.00 0.91 2.98 2.11 -3.92 2.63 2.18 1.03 3.08 17 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 20 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 15 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 2000 | 2.27 | 2.11 | 1.23 | 3.16 | 1.26 | 2.00 | 1.42 | 1.71 | 1.81 | 1.43 | 1.83 | 1.11 | 23.53 |
| 1997 1.37 -0.10 1.26 0.10 1.44 3.04 0.93 0.93 1.47 1.82 4.14 2.80 20 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 15 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 1999 | 0.77 | 1.31 | 1.75 | 3.92 | 2.43 | 2.24 | 1.43 | 0.85 | 1.97 | 1.87 | 1.98 | 1.55 | 24.40 |
| 1996 1.03 0.96 1.27 1.37 1.25 0.31 1.75 1.32 1.62 0.90 0.99 1.68 15 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 1998 | 0.34 | 2.23 | 1.44 | 1.00 | 0.91 | 2.98 | 2.11 | -3.92 | 2.63 | 2.18 | 1.03 | 3.08 | 17.01 |
| 1995 1.57 3.20 1.81 0.95 0.83 3.06 2.42 1.59 2.25 0.22 2.54 1.67 24 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 1997 | 1.37 | -0.10 | 1.26 | 0.10 | 1.44 | 3.04 | 0.93 | 0.93 | 1.47 | 1.82 | 4.14 | 2.80 | 20.89 |
| 1994 0.21 -0.14 1.64 0.95 1.88 0.53 1.99 1.83 0.65 0.90 1.53 2.58 15 | 1996 | 1.03 | 0.96 | 1.27 | 1.37 | 1.25 | 0.31 | 1.75 | 1.32 | 1.62 | 0.90 | 0.99 | 1.68 | 15.44 |
| | 1995 | 1.57 | 3.20 | 1.81 | 0.95 | 0.83 | 3.06 | 2.42 | 1.59 | 2.25 | 0.22 | 2.54 | 1.67 | 24.44 |
| 1993 1.20 1.35 1.95 -2.10 0.45 2.10 1.65 2.23 2.19 3.60 1.55 2.58 20 | 1994 | 0.21 | -0.14 | 1.64 | 0.95 | 1.88 | 0.53 | 1.99 | 1.83 | 0.65 | 0.90 | 1.53 | 2.58 | 15.52 |
| | 1993 | 1.20 | 1.35 | 1.95 | -2.10 | 0.45 | 2.10 | 1.65 | 2.23 | 2.19 | 3.60 | 1.55 | 2.58 | 20.32 |

Performance has been presented net of fees. THE FIGURES RELATING TO PAST PERFORMANCE REFER OR RELATE TO PAST PERIODS AND ARE NOT A RELIABLE INDICATOR OF FUTURES RESULTS. THIS ALSO APPLIES TO HISTORICAL MARKET DATA. To the extent any performance shown herein is hypothetical, such performance results have many inherent limitations. There are frequently sharp differences between a hypothetical composite performance record and the actual record subsequently achieved and an individual investor may have experienced different results for the period in question had it been an investor during such period. HYPOTHETICAL PERFORMANCE RESULTS HAVE MANY INHERENT LIMITATIONS, SOME OF WHICH ARE DESCRIBED BELOW. NO REPRESENTATION IS BEING MADE THAT THE FUND WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THE HYPOTHETICAL PERFORMANCE RESULTS SUBSEQUENTLY ACHIEVE DESCRIBED BELOW. NO REPRESENTED HEREIN. IN ACT., THERE ARE FREQUENTLY SHARP DIFFERENCES BETWEEN HYPOTHETICAL PERFORMANCE RESULTS AND THE ACTUAL RESULTS SUBSEQUENTLY ACHIEVE DESCRIPTION OF HINDSIGHT. IN ADDITION, HYPOTHETICAL PERFORMANCE RESULTS SIST HAT AT THEY ARE GENERALLY PREPARED WITH THE BENEFIT OF HINDSIGHT. IN ADDITION, HYPOTHETICAL TRADING DOES NOT INVOLVE FINANCIAL RISK, AND NO HYPOTHETICAL TRADING RECORD CAN COMPLETELY ACCOUNT FOR THE IMPACTION. FINANCIAL RISK IN ACTUAL TRADING DOSSES OR TO ADHERE TO A PARTICULAR TRADING PROGRAM IN SPITE OF TRADING LOSSES ARE MATERIAL POINTS WHICH CAN ALSO ADVERSELY AFFECT ACTUAL TRADING RESULTS. THERE ARE NUMEROUS OTHER FACTORS RELATED TO THE MARKETS IN GENERAL ORTO THE IMPLEMENTATION OF ANY SPECIFIC TRADING PROGRAM WHICH CANNOT BE FULLY ACCOUNTED FOR IN THE PREPARATIATION OF HYPOTHETICAL PERFORMANCE RESULTS AND ALL OF WHICH CAN ADVERSELY AFFECT ACTUAL TRADING RESULTS.

FUND CHARACTERISTICS

| | | CLASS I | CLASS A | | | |
|----------------------------|--------------------------|--|--|--|--|--|
| Currencies | | EUR, USD, JPY, CHF, GBP, SEK, NOK, SGD | | | | |
| Type of shares | | Capitalisation | | | | |
| Management Fee | | 0.40% (up to 0.50%) | 1.25% | | | |
| Class Investment A | dvisory Fee | 1.00 % | | | | |
| Performance Fee | | 20%, subject to high watermark | | | | |
| Administrative Fee | | Max 0.25% p.a. ** | | | | |
| Minimum Initial Investment | | \$ 100,000 | \$ 10,000 | | | |
| ISIN | USD EUR GBP CHF | IE00B905SX62 IE00B8BS6228 IE00B9CB6D86 IE00B9CBVV18 | IE00B8HSRJ09 IE00B9DCSJ09 IE00B9B30X37 IE00B84HYP51 | | | |

DISCLAIMER

The information contained in this document is provided to you confidentially and for exclusive use, and in no way constitutes an offer to buy, investment advice, a solicitation to sell or the basis of an agreement or a commitment of any sort. All forecasts, valuations and statistical analyses included in this document are provided for information purposes only. These forecasts, valuations and analyses may be based on subjective estimates and assumptions and may have been obtained by applying one of a number of methods that may give rise to different results; accordingly, these forecasts, valuations and analyses must not be seen as factually accurate and should not be considered to be accurate predictions of future events. The accuracy, completeness and relevance of the information provided are not guaranteed: although this information has been prepared by reference to reputable sources that are considered to be reliable, it may be amended without notice. This information increasing partial, provided on the basis of market data observed at a particular moment, and subject to change. Lyxor Asset Management accepts no liability, whether direct or indirect, that may result from using any information contained in this document or from any decision taken on the basis of the information contained threin. This information must not be copied, reproduced, amended, translated or distributed without the prior written consent of Lyxor Asset Management. Data from rating agencies are provided to you only by virtue of the authorisations that have been granted by those rating agencies. You must notify us as soon as possible in the event that there is any change to these authorisations.

PROFILE | JUNE 2022

EQUITY

LEGAL STRUCTURE Sub-fund of Lyxor Newcits IRL, an Irish UCITS umbrella

FUND INCEPTION DATE 21/02/2013

SHARE CLASS LAUNCH DATE

REFERENCE CURRENCY USD

LIQUIDITY' Daily

DEADLINE FOR PLACEMENT OF ORDERS

On D day 10:00 AM (Dublin time)

SETTLEMENT

D+3 business days

INVESTMENT MANAGER

Lyxor Asset Management S.A.S.

SUB-INVESTMENT MANAGER TIG Advisors LLC

ADMINISTRATOR

SS&C GlobeOp Financial Services

* Under normal market conditions, Lyxor intends to offer the LIQUIDITY mentioned above. However, the LIQUIDITY is not guaranteed and there are circumstances under which such LIQUIDITY may not be possible.

** The Fund is subject to an Administrative Expenses fee at a rate of up to 0.25% of the Net Asset Value of each Class of the Sub-Fund per annum. Please refer to the Fund's legal documentation for complete terms and conditions.

Please refer to the Fund's legal documentation for complete terms and conditions.

MAIN RISKS

Potential investors should be aware that any direct or indirect investment in any security or investment vehicle described herein is subject to significant risks, including total loss of capital, and that there are significant restrictions on transferability and redemption of any such security or interests in any such investment vehicle. Investors should be able to bear the financial risks and limited liquidity of their investment. The Fund has a limited operating history.

> Lyxor Asset Management 91-93, boulevard Pasteur 75015 Paris - France lyxor-crm@lyxor.com +33 1 42 13 31 31 Registration number: GP98019



LYXOR / TIEDEMANN ARBITRAGE STRATEGY FUND

EQUITY

Class I - USD

GLOSSARY

Annualized Return – a rate of return for a given period that is less than one year, but that is computed as if the rate were for a full year. The formula is as follows assuming that M is the total number of months of returns which are being measured within the Program: (1+Cumulative Returns)^(12/M)-1. Annualized Volatility – the square root of 12 multiplied by the Standard Deviation. Sharpe Ratio– this is a formula used to measure risk-adjusted performance. This is calculated by subtracting the risk-free rate (in this case, 3M T-bill) from the rate of return for the Program and

dividing the result by the Standard Deviation.

INDICES

Indices are unmanaged and do not include fees, expenses or other transaction costs associated with the portfolio. Any comparison of performance with an index is subject to material limitations. References to an index do not imply that the portfolio is intended to achieve returns or volatility or results similar to such index. Euribor - Euribor (Euro Interbank Offered Rate) is a daily reference rate, based on the averaged interest rates at which Eurozone banks offer to lend unsecured funds to other banks in the euro wholesale money market.

NOTICE

Notice to European Investors: Any potential investment in any securities or financial instruments described herein may not be suitable for all investors. Any prospective investment will require you to represent that you are a " professional client " as defined in the Markets in Financial Instruments Directive ("MiFID"). The securities and financial instruments described herein may not be available in all iurisdictions.

Notice to French Investors: The intent to market the units of the Fund in France has been duly notified to the French "Autorité des marchés financiers"

For Investors in the United Kingdom: This material is issued in the United Kingdom by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658. The Fund is registered in the UK Temporary Marketing Permissions Regime (TMPR) and shares/units in the Fund may upon such registration be promoted and sold to the general public in the United Kingdom subject to compliance with the TMPR and applicable regulations under TMPR. Potential investors in the United Kingdom should be aware that most of the content and the temperature will the the intervention will get be available in the United Kingdom should be aware that most of the content and the temperature will be the divertee will get be available in the United Kingdom should be aware that most of the content and the temperature will get be available to the solution of the solution of the temperature will get be available to the temperature will get be available to the solution of th protections afforded by the United Kingdom regulatory system will not apply to an investment in the fund and that compensation will not be available under the United Kingdom Financial Services Compensation Scheme.

Notice to Italian Investors: The intent to market the units of the Fund in Italy has been duly notified to CONSOB. Before subscribing or purchasing, read carefully the prospectus approved by the Central Bank of Ireland, as available on website www.Lyxorfunds.com and at the offices of Amundi Asset Management – Via Cernaia, 8/10, 20121 Milano MI, Italy, in which documents the characteristics, the risk factors and the costs are described in detail.

Notice to Spanish Investors: The Fund has been registered in the CNMV for its marketing in Spain.

Notice to Swiss Investors: Financial intermediaries (including particularly, representatives of private banks or independent asset managers, Intermediaries) are hereby reminded on the strict regulatory requirements applicable under the Collective Investment Schemes Act – Federal Law of 2006 (CISA) to any distribution of foreign collective investment schemes in Switzerland. It is each Intermediary's sole responsibility to ensure that (i) all these requirements are put in place prior to any Intermediary distributing any of the Funds presented in this document and (ii) that otherwise, it does not take any action that could constitute distribution of collective investment schemes in Switzerland as defined in article 3 CISA and related regulation. Any information in this document is given only as of the date of this document and is not updated as of any date thereafter. This document is not a prospectus as per article 652a or 1156 of the Swiss Code of Obligations, a listing prospectus according to the listing rules of the SX Swiss Exchange or any other trading venue as defined by the Swiss Financial Market Infrastructure Act of 19 June 2015 (as amended from time to time, FMIA), a simplified prospectus, a key investor information document or a prospectus as defined in the CISA. An investment in collective investment schemes involves significant risks that are described in each prospectus or offering memorandum. Each optertal investor schemes involves investors and disclosures before making an investment in collective investment of collective the restructure schemes involves significant risks that are described in each prospectus or offering memorandum. Each opter the investor and disclosures before making an investment in collective investment schemes involves significant risks that are described in each prospectus or offering memorandum. a key linkestor mioritation document of a prospectus as defined in the OSA. An investment in concurrent instruction structure investment structures involves and are described in each prospectus or offering memorandum. Each potential investor should carefully consider the risk warnings and disclosures before making an investment decision. Any benchmarks/indices cited in this document are provided for information purposes only. This document is not the result of a financial analysis and therefore is not subject to the "Directive on the Independence of Financial Research" of the Swiss Bankers Association. This document does not contain personalized recommendations or advice and is not intended to substitute any professional advice on investments in financial products. The Representative and the Paying Agent of the Fund(s) in Switzerland is Société Générale, Paris, Zurich Branch, Talacker 50, 8001 Zurich. The prospectus or offering memorandum, the key investor information documents, the management regulation, the articles of association and/or any other constitutional documents as well as the annual investition for the Darcentter in Suitardian documents as well as the annual comments as well as the annual for the particular products. and semi-annual financial reports may be obtained free of charge from the Representative in Switzerland.

Notice to German Investors: The Prospectus in English and the Key Investor Information in German are available free of charge in paper form from Lyxor International Asset Management S.A.S. Deutschland (Lyxor Germany), Neue Mainzer Strasse 46-50, 60311 Frankfurt am Main, Germany, or electronically under www.lyxorfunds.com.

Notice to Canadian Investors: Any potential investment in any securities or financial instruments described herein may not be suitable for all investors. Any prospective investment will require you to represent that you are a "permitted client", as defined in National Instrument 31-103 and an "accredited investor", as defined in National Instrument 45-106. The securities and financial instrument described herein may not be available in all jurisdictions of Canada. Investment vehicles described herein may not be available in all jurisdictions of Canada. Investment vehicles described herein may not be available in all jurisdictions of Canada. Investment vehicles described herein may not be available in all jurisdictions of Canada. Investment vehicles described herein may not be available in all jurisdictions of Canada. Investment vehicles described herein will not be offered by prospectus in Canada and will not be subject to National Instrument 81-102 and National Instrument 81-106. In addition, investments in or linked to hedge funds are highly speculative and may be adversely affected by the unregulated nature of hedge funds and the use of trading strategies and techniques that are typically prohibited for prospectus offered funds. Also, hedge funds are typically less transparent in terms of information and pricing and have much higher fees than prospectus offered funds. Investors in hedge funds may not be afforded the same protections as investors in offered funds, including limitations on fees, controls over investment policies and reporting requirements

Notice to Investors in Asia-Pacific Region: This document is not directed at retail investors and is prepared for and intended to be distributed in the Asia-Pacific region solely to sophisticated and professional investors. You should therefore be appropriately qualified as a professional, accredited, wholesale, expert or institutional investor (however defined in your local jurisdiction). It is distributed by licensed affiliates of Amundi AM. You should be aware that local regulations may not allow this document to be distributed from your local Amundi AM licensed affiliate but may allow it to be distributed from an offshore branch or affiliate under certain circumstances. If in any doubt, you should always determine which licensed affiliate is responsible for distributing this document to you by contacting Amundi AM. You should also be aware that financial products or services referred to may not be sold, bought, or subscribed to if you do not qualify in your local jurisdiction. Always ensure that you contact and deal through appropriately licensed entities if you wish to purchase any such products or services

No further disclosure, reproduction or reliance permitted: This document has been prepared solely for persons it has been distributed to directly by Amundi AM or any of its affiliates or delegates. Its contents may not be disclosed to, reproduced, or used or relied upon by, any other person, or used for any other purpose.

For Recipients where this document is distributed by Amundi Hong Kong Limited: This document is distributed to you by Amundi Hong Kong Limited ("Amundi HK") as an activity that is wholly incidental to its carrying out of a regulated activity for which it is already licensed. Details of Amundi HK's license can be provided upon request.

Amundi HK has been appointed by LAM, LIAM, and Lyxor Funds Solutions S.A. (together "Lyxor") to promote the funds launched by Lyxor. Investors and prospective investors should note that a service fee may be paid by Lyxor to Amundi HK for its services.

For Recipients In Hong Kong: This document is issued solely to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

For Recipients in Singapore: This document may only be provided to institutional investors, as defined in Section 4A of the Securities and Futures Act. If you wish to discuss this document or effect transactions in any security discussed herein, you should do so with or through MAS licensed representatives of Amundi Singapore Limited (Company Registration No. 198900774E).

For Documents Distributed in China from Offshore (as a Result of a Reverse Enquiry): This document has been prepared and distributed by Amundi Hong Kong Limited as a result of a reverse enquiry by you. Amundi HK, a limited liability company incorporated under the laws of Hong Kong on 9 March 1973 and regulated by the Financial Supervisory Commission (the "SFC"). The products or services that may be mentioned in this document may not be able to be provided in China. Any products or services mentioned in this document to be provided are subject to laws and regulations and regulator's requirements in China, as well as the formally executed legal documents (if any)



Class I - USD

EQUITY

Notice to Korean Investors: This document is distributed by Amundi Hong Kong Limited outside Korea and intended for Korean financial institutions holding the dealing or brokerage business license under the Financial Investment and Capital Market Act of Korea and the Enforcement Decree thereof. For other types of clients, this is distributed upon their request only. Amundi Hong Kong Limited is regulated by the Securities & Futures Commission under Hong Kong laws. The product mentioned in this document may not be eligible or suitable for all types of investors. This document is not intended for private customers.

For Korean Investors receiving this document from NH-Amundi Asset Management: This document is distributed by NH-Amundi Asset Management. NH-Amundi Asset Management is regulated by the Financial Services Commission and the Financial Supervisory Service under Korean laws. The product mentioned in this document may not be eligible or suitable for all types of investors. This document is not intended for private customers.

Notice for Documents Distributed in Taiwan: This document is to present to you as a result of reverse enquiry and may only be distributed to "professional institutional investors" within the meaning provided in the applicable regulations in Taiwan. The product(s) or service(s), if any, mentioned in this document, have not been registered with or approved by Taiwan competent authorities and are not regulated by Taiwan laws and regulations. The Fund has not been and will not be registered with the Financial Supervisory Commission (the "FSC") of Taiwan, the Republic of China ("Taiwan") pursuant to applicable securities laws and regulations and any sale of the interests in the Fund ("Interest") in Taiwan shall be in compliance with the local legal requirements and restrictions. There are restrictions on the offering, issue, distribution, transfer, sale or resale of the Interests in Taiwan, either through a public offering or private placement. The Interests cannot be sold, issued or publicly offered in Taiwan and sale of the Interests.

For Recipients in Thailand receiving this document from offshore: This document has been prepared and distributed by Lyxor Asset Management S.A.S and/or its affiliates within Amundi Group ("LAM"). This document is provided solely at your request and LAM and its affiliates do not have any intention to solicit you for entering into any transactions or transacting in any product contemplated by this document (the "product"). Any such solicitation or marketing will be made by an entity permitted by the applicable laws and regulations. This document is not intended to be either an offer, sale, or invitation for subscription or purchase of the product. This document has not been registered as a prospectus with the Office of the Securities and Exchange Commission of Thailand. Accordingly, this document and any other documents and materials, in connection with the offer or sale, or invitation for subscription or purchase of securities and regulations. Neither LAM, any of its affiliates, any representatives, directors, employees of LAM nor any other entities affiliated with LAM make any representations or warranties, expressed or implied, with respect to the completeness or accuracy of any of the information contained in this document or any other information (whether communicated in written or oral form) transferred or made available to you. Investments in the product involves risks and investors should exercise due care and discretion in considering the investment risks. Investors should carefully study the investment risks and ensure that they have a good understanding of such risks.

Notice to Malaysian Investors: This material has been provided to you at your specific request. This material has not been or will not be registered or filed under the securities law or with any security's regulatory authority in Malaysia. Under no circumstances shall this material constitute an offer in Malaysia to sell or the solicitation in Malaysia of an offer to buy, the products described herein. This document has been prepared by Lyxor Asset Management S.A.S and/or its affiliates within Amundi Group ("LAM") and distributed by LAM, Amundi Hong Kong Limited or its affiliates within Amundi Group outside Malaysia at your specific request. Amundi Malaysia Sdn. Bhd. (Registration No. 200801015439 (816729-K) has not been involved with the preparation or distribution of this document. Any products or service that may be mentioned in this document are subject to local laws and regulations and may not be able to be provided in your jurisdiction under certain circumstances.

IMPORTANT INFORMATION FOR INVESTORS

Regarding the benchmark index mentioned in this document: Parties entering into transactions (such as a derivative or financing transaction) or investing in financial instruments that use a benchmark index are exposed to the risk that: (1) such benchmark index may be subject to methodological or other changes which could affect the value of the relevant transaction; or (2) (i) may become not compliant with applicable laws and regulations (such as the European Benchmark Regulation), (ii) may cease to be published, or (iii) the supervisor or administrator of any such benchmark may make a statement that the relevant benchmark is no longer representative, and as a consequence the relevant benchmark may be replaced by another benchmark which may have an adverse and material impact on the economics of the relevant transactions. You should conduct your own independent investigation and analysis of the potential consequences of any relevant risks such as those mentioned above, particularly in light of the ongoing industry initiatives related to the development of alternative reference rates and the update of the relevant market standard documentation.

